Intravenous Thrombolysis for Ischemic Stroke Patients on Dual Antiplatets: Tsivgoulis, G, Katsanos, AH, Mavridis, D et al. Annals of Neurology. 2018;84:89-97

Abstract

In patients who receive intravenous thrombolytic therapy for ischemic stroke, prior use of dual antiplatelet therapy has been linked to high rates of adverse effects from tissue plasminogen activator (tPA). Specifically, increased rates of symptomatic intracranial hemorrhage have been reported. It is unclear if this is due to the antiplatelet therapy itself or due to other comorbidities present in patients typically prescribed dual antiplatelet therapy.